Treating HER2-mutant advanced biliary tract cancer with neratinib: Benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket; trial Meeting Abstract
| Authors: | Harding, J.; Cleary, J.; Shapiro, G.; Braña, I.; Moreno, V.; Quinn, D.; Borad, M.; Loi, S.; Spanggaard, I.; Stemmer, S.; Dujka, M.; Cutler, R.; Xu, F.; Eli, L.; Macia, S.; Lalani, A.; Bryce, R.; Bernstam, F. M.; Solit, D.; Hyman, D.; Piha-Paul, S. |
| Abstract Title: | Treating HER2-mutant advanced biliary tract cancer with neratinib: Benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket; trial |
| Meeting Title: | ESMO 21st World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Jul 3-6 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-07-01 |
| Start Page: | iv127 |
| Language: | English |
| ACCESSION: | WOS:000475860200004 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz154.004 |
| Notes: | Meeting Abstract: O-005 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work